Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim, a Germany-based contract manufacturer, has acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California.
Subscribe to our email newsletter
The transaction involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site.
The facility consists of more than 200,000 square feet for laboratories, manufacturing and process development suitable for clinical and market supplies.
As a fully integrated manufacturing site, the Fremont site complements the existing capabilities and technology found across the existing Boehringer Ingelheim biopharma network located in Biberach/Germany and Vienna/Austria.
Boehringer Ingelheim Biopharmaceuticals corporate senior vice president Simon Sturge said the strategic decision to have a contract manufacturing facility in the US Bay Area biotechnology cluster will complement their goal to further increase the company’s world leading position in the process development and manufacture of Biopharmaceuticals.